CenterBook Partners LP Has $15.92 Million Stake in CG Oncology, Inc. $CGON

CenterBook Partners LP increased its stake in shares of CG Oncology, Inc. (NASDAQ:CGON) by 52.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 395,340 shares of the company’s stock after acquiring an additional 135,241 shares during the quarter. CG Oncology makes up about 0.8% of CenterBook Partners LP’s portfolio, making the stock its 24th largest position. CenterBook Partners LP owned approximately 0.52% of CG Oncology worth $15,924,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Winthrop Capital Management LLC bought a new stake in CG Oncology in the 2nd quarter valued at about $38,000. Strengthening Families & Communities LLC bought a new stake in shares of CG Oncology during the third quarter valued at approximately $40,000. PNC Financial Services Group Inc. raised its position in shares of CG Oncology by 15.2% during the second quarter. PNC Financial Services Group Inc. now owns 3,279 shares of the company’s stock worth $85,000 after purchasing an additional 433 shares during the period. CWM LLC lifted its holdings in shares of CG Oncology by 193.5% in the 2nd quarter. CWM LLC now owns 6,193 shares of the company’s stock worth $161,000 after purchasing an additional 4,083 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in CG Oncology by 159.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock valued at $182,000 after purchasing an additional 4,288 shares during the period. 26.56% of the stock is owned by institutional investors.

CG Oncology Price Performance

Shares of CG Oncology stock opened at $53.87 on Wednesday. The firm has a market cap of $4.35 billion, a PE ratio of -26.41 and a beta of 1.32. CG Oncology, Inc. has a 1 year low of $14.80 and a 1 year high of $57.88. The stock has a fifty day moving average price of $47.59 and a 200-day moving average price of $40.52.

Insider Buying and Selling

In other news, Director James Mulay sold 11,145 shares of the stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $52.47, for a total transaction of $584,778.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Wall Street Analysts Forecast Growth

CGON has been the topic of a number of recent research reports. Truist Financial raised their price objective on shares of CG Oncology from $66.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, February 10th. Piper Sandler lifted their price target on CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. The Goldman Sachs Group reissued a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a report on Monday, January 12th. Royal Bank Of Canada raised their target price on CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Finally, Morgan Stanley set a $93.00 price target on CG Oncology in a report on Friday, January 9th. Eleven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.58.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.